
Frontiers in Cancer Immunotherapy
Monday, February 27, 2017 - Tuesday, February 28, 2017
The New York Academy of Sciences
Presented By
Cancer immunotherapy—the use of the immune system to treat cancer—is one of the most promising therapies to emerge since the development of chemotherapy in the mid-twentieth century. Harnessing the body's own innate defense mechanisms to attack cancer cells has demonstrated potential for developing treatments that are not only more efficacious (including long-lasting remissions and progression-free survival rates), but also more precise. Importantly, increased precision may reduce the toxicity that is often experienced with current pharmaceutical interventions. Different immunotherapeutic approaches, ranging from activating the patient's own immune response to attack cancer cells to neutralizing mechanisms designed to regulate and suppress patient's immune systems, are increasingly implemented in the regimen of oncology clinical care with positive results.
This 2-day scientific symposium will explore emerging findings in basic science, translational research, and clinical studies to improve immunotherapeutic approaches in cancer treatment. The event will convene basic, preclinical, and clinical researchers active in the field of cancer immunotherapy, alongside industry representatives and government stakeholders. Dr. Padmanee Sharma, Professor of Genitourinary Medical Oncology and of Immunology at the University of Texas MD Anderson Cancer Center, will commence the conference with a Keynote Address. Plenary speakers will present on an array of topics, including: the evaluation of combination therapy strategies to improve clinical benefit; the development of immune-monitoring strategies for the identification of relevant prognostic and predictive biomarkers; the development of strategies to overcome immune tolerance; and the incorporation of genomics into immunotherapeutic research and clinical trials.
Registration Pricing
By 2/3/2017 | After 2/3/2017 | Onsite | |
Member | $175 | $200 | $250 |
Student/Postdoc Member | $150 | $175 | $225 |
Nonmember (Academia) | $250 | $300 | $375 |
Nonmember (Corporate) | $350 | $400 | $475 |
Nonmember (Non-profit) | $250 | $300 | $375 |
Nonmember (Student/Postdoc/Fellow) | $175 | $200 | $350 |
Paid registration includes a complimentary, one-year membership to the New York Academy of Sciences. Complimentary memberships are provided to non-members only and cannot be used to renew or extend existing or expiring memberships. A welcome email will be sent upon registration which will include your membership credentials.
On March 1, 2017, The New York Academy of Sciences' Cancer and Signaling Discussion Group will present a satellite symposium titled, Quantitative Approaches in Immuno-Oncology. This symposium will explore the emerging field of quantitative immuno-oncology, covering the breadth of scientific topics and methods needed to quantify interactions between tumors and the immune system.
To learn more and register, visit www.nyas.org/QIO2017.
Organizers
Keynote Speaker
Speakers
Sponsors
For sponsorship opportunities please contact Kari Fischer, PhD, at kfischer@nyas.org or 212.298.8648.
Grant Support
This program is supported in part by educational grants from AstraZeneca, Bristol-Myers Squibb, Genentech, Incyte, and Prometheus Laboratories Inc.
Gold Sponsor

Bronze Sponsors
Academy Friend
Promotional Partners
Damon Runyon Cancer Research Foundation
American Journal of Clinical Oncology
Journal of Cellular Immunotherapy
Presented by
![]() | ![]() | |
![]() | ![]() |

Agenda
* Presentation titles and times are subject to change.
Day 1: February 27, 2017 | |
7:45 AM | Breakfast and Registration |
8:30 AM | Introduction and Welcome Remarks |
8:55 AM | Keynote Address: |
Session 1: Assessment of Current Therapeutic Approaches in Cancer Immunotherapy: Successes and ChallengesSession Chair: Jedd D. Wolchok, MD, Memorial Sloan Kettering Cancer Center | |
9:40 AM | Engineering T Cells to Be Effective in Tumor Therapy |
10:05 AM | Modulation of Immunity through Dendritic Cell Targeting |
10:30 AM | Treating the Tumor and Treating the Host |
10:55 AM | Networking Coffee Break |
Session 2: Evaluation of Combination Therapy Strategies to Improve Clinical OutcomesSession Chair: Michele Maio, PhD, University Hospital, Sienna | |
11:25 AM | Immunologic Checkpoint Blockade: Exploring Combinations and Mechanisms |
11:50 AM | The Promise of Epigenetic Therapies for Enhancing the Efficacy of Immune Checkpoint Therapy |
12:15 PM | Therapeutic Vaccination for Premalignant HPV Disease: It's Getting Better All the Time |
12:40 PM | Networking Lunch and Poster Viewing |
12:55 PM | Underrepresented Minorities, Women, and Early Career Investigator Career Development Workshop and Lunch Running Concurrently with the Networking Lunch Editor's Guide to Writing and Publishing Your Paper |
Session 3: Identification of Relevant Prognostic and Predictive Biomarkers for the Development of Immune-Monitoring StrategiesSession Chair: Angela Colmone, PhD, Science Immunology | |
2:00 PM | Inflammation and Cancer: Fueling Response and Resistance of Immunotherapies |
2:25 PM | T cell Receptor Responses in Health and Disease |
2:50 PM | Melanoma Response and Resistance to PD-1 Blockade Therapy |
3:15 PM | Networking Coffee Break |
Session 4: Development of Strategies to Overcome Immune ToleranceSession Chair: Kunle Odunsi, MD, PhD, Roswell Park Cancer Institute | |
3:40 PM | Tumor and Host Pathways that Shape Degrees of Immunotherapy Resistance |
4:05 PM | Molecular and Epigenetic Programs Underlying CD8 T Cell Dysfunction in Solid Tumors |
4:30 PM | Targeting FoxP3+ T-cells in Cancers; Friends or Foes? |
4:55 PM | Emerging Technologies in Cancer Immunotherapy |
5:20 PM | Panel Discussion — Day 1 Wrap-up Philip D. Greenberg, MD, University of Washington |
5:45 PM | Closing Remarks |
5:55 PM | Poster Session 1 and Networking Reception |
7:00 PM | Day 1 Adjourns |
Day 2: February 28, 2017 | |
8:00 AM | Breakfast and Registration |
8:00 AM | Underrepresented Minorities, Women, and Early Career Investigator Mentoring Breakfast Running Concurrently with the General Breakfast Mentors: |
Session 5: Clinical Research Break Out Sessions | |
9:00 AM | Breakout Group 1: How to Manage Toxicities in Cancer Immunotherapy? |
Breakout Group 2: How to Incorporate Biomarkers into Early Phase Immunotherapy Trials? | |
Breakout Group 3: What are the Latest Strategies for Cancer Immunotherapy Development — a Pharmaceutical Industry Perspective? | |
10:00 AM | Networking Coffee Break |
Session 6: Optimizing Incorporation of Cancer Genomics and Epigenomics into Immunotherapy Research and Clinical StrategiesSession Chair: Laurence Zitvogel, MD, PhD, Institut National de la Santé et Recherche Médicale | |
10:30 AM | T-cell Adoptive Therapy Moves Beyond Melanoma |
10:55 AM | Epigenetic Immunomodeling for Cancer Immunotherapy |
11:20 AM | Immunotherapeutic Responses to Cancer Neoantigens |
11:45 AM | Networking Lunch and Poster Session 2 |
Session 7: Targeting T-cells in Cancer ImmunotherapySession Chair: Philip D. Greenberg, MD, University of Washington | |
1:15 PM | Regulatory T-cells and Strategies for Inhibition for Cancer Therapy |
1:40 PM | Chimeric Antigen Receptors: Progress and Challenges |
2:05 PM | Targeting Tryptophan Metabolism to Overcome Negative Regulation of Antitumor Immunity in Ovarian Cancer |
2:30 PM | Networking Coffee Break |
Session 8: Hot Topic Short TalksSession Chair: Hiroyoshi Nishikawa, MD, PhD, National Cancer Center Hospital, Japan | |
3:00 PM | Activating the Brain to Fight Cancer: Reward System Activation Attenuates Tumor Growth in Mice |
3:15 PM | MEX3B Mediates Resistance to T cell-based Immunotherapy by Impairing Antigen Processing and Presentation |
3:30 PM | Fatty Acid Metabolism Limits an Oxidative Stress Response that Promotes T Cell Exhaustion During Rapid Clonal Proliferation |
3:45 PM | Tissue-specific Efficacy and Safety of Checkpoint Blockade Combination Immunotherapy |
4:00 PM | Inducing New Systemic Immune Responses and Frequent Durable Complete Regressions (CRs) of Human Metastatic Melanoma with Intralesional Secreted Cytokines |
Session 9: Emerging Technologies in Cancer ImmunotherapySession Chair: Melanie Brickman Borchard, PhD, MSc, The New York Academy of Sciences | |
4:15 PM | Role of the Human Intestinal Microbiome in the Response to PD1 Blockade in Advanced Cancer |
4:40 PM | Closing Remarks |
4:50 PM | Conference Adjourns |
Organizers
James P. Allison, PhD
The University of Texas MD Anderson Cancer Center
Melanie Brickman Borchard, PhD, MSc
The New York Academy of Sciences
website
Jonathan Cebon, MBBS, PhD, FRACP
Olivia Newton-John Cancer and Wellness Centre
Angela Colmone, PhD
Science Immunology
Philip D. Greenberg, MD
University of Washington
Brooke Grindlinger, PhD
The New York Academy of Sciences
website
Priscilla Kelly, PhD
Science
Michele Maio, MD, PhD
University Hospital, Sienna
Kristen Mueller, PhD
Science
Hiroyoshi Nishikawa, MD, PhD
National Cancer Center, Japan
Yevgeniya Nusinovich, MD, PhD
Science Translational Medicine
Kunle Odunsi, MD, PhD
Roswell Park Cancer Institute
Daniel Radiloff, PhD
The New York Academy of Sciences
Jedd D. Wolchok, MD, PhD
Memorial Sloan Kettering Cancer Center
Laurence Zitvogel, MD, PhD
Institut National de la Santé et Recherche Médicale
Keynote Speaker
Padmanee Sharma, MD, PhD
The University of Texas MD Anderson Cancer Center
Speakers
Stephen B. Baylin, MD
Johns Hopkins University
Nina Bhardwaj, MD, PhD
Icahn School of Medicine at Mount Sinai
Lisa Coussens, PhD
Oregon Health Sciences University
website
Mark Davis, PhD
Stanford University
Thomas Gajewski, MD, PhD
University of Chicago
Sacha Gnjatic, PhD
Mount Sinai School of Medicine
Matthew Gubin, PhD
Washington University in St. Louis
Carl June, MD
University of Pennsylvania
Ronald Levy, MD
Stanford University
website
Crystal Mackall, MD
Stanford University
Ira Mellman, PhD
Genentech
Kunle Odunsi, MD, PhD
Roswell Park Cancer Institute
Antoni Ribas, MD, PhD
University of California Los Angeles
website
Alexander Rudensky, PhD
Memorial Sloan Kettering Cancer Center
Andrea Schietinger, PhD
Memorial Sloan Kettering Cancer Center
website
Connie Trimble, MD
Johns Hopkins University
James C. Yang, MD
National Cancer Institute, U.S. National Institutes of Health
Travel & Lodging
Our Location
The New York Academy of Sciences
7 World Trade Center
250 Greenwich Street, 40th floor
New York, NY 10007-2157
212.298.8600
Hotels Near 7 World Trade Center
Recommended partner hotel
Club Quarters, World Trade Center
140 Washington Street
New York, NY 10006
Phone: 212.577.1133
The New York Academy of Sciences is a member of the Club Quarters network, which offers significant savings on hotel reservations to member organizations. Located opposite Memorial Plaza on the south side of the World Trade Center, Club Quarters, World Trade Center is just a short walk to the Academy.
Use Club Quarters Reservation Password NYAS to reserve your discounted accommodations online.
Other nearby hotels
212.945.0100 | |
212.693.2001 | |
212.385.4900 | |
212.269.6400 | |
212.742.0003 | |
212.232.7700 | |
212.747.1500 | |
212.344.0800 |